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Zinc is a transmembrane agonist that induces
platelet activation in a tyrosine phosphorylation-
dependent manner
Ben R. Watson,a Nathan A. White,b Kirk A. Taylor,b Joanna-Marie Howes,a
Jean-Daniel M. Malcor,a Dominique Bihan,a Stewart O. Sage,c Richard W. Farndalea
and Nicholas Pugh*ab
Following platelet adhesion and primary activation at sites of vascular injury, secondary platelet
activation is induced by soluble platelet agonists, such as ADP, ATP, thrombin and thromboxane. Zinc
ions are also released from platelets and damaged cells and have been shown to act as a platelet agonist.
However, the mechanism of zinc-induced platelet activation is not well understood. Here we show that
exogenous zinc gains access to the platelet cytosol and induces full platelet aggregation that is dependent
on platelet protein tyrosine phosphorylation, PKC and integrin aIIbb3 activity and is mediated by granule
release and secondary signalling. ZnSO4 increased the binding aﬃnity of GpVI, but not integrin a2b1. Low
concentrations of ZnSO4 potentiated platelet aggregation by collagen-related peptide (CRP-XL), thrombin
and adrenaline. Chelation of intracellular zinc reduced platelet aggregation induced by a number of
diﬀerent agonists, inhibited zinc-induced tyrosine phosphorylation and inhibited platelet activation in
whole blood under physiologically relevant flow conditions. Our data are consistent with a transmembrane
signalling role for zinc in platelet activation during thrombus formation.
Introduction
Platelets are the principal cellular determinants of haemostasis
and pathological thrombus formation leading to myocardial
infarction and stroke. Following adhesion to sites of vascular
damage, platelets undergo primary activation leading to shape
change, upregulation of integrin aIIbb3 activity and secretion of
alpha and dense granules.1 Granule release introduces bioactive
molecules into the immediate environment of a growing thrombus.
Such molecules include adhesion proteins, coagulation factors and
soluble platelet agonists, such as ADP, ATP, thromboxane-A2
and zinc.2–4
Plasma zinc concentration ranges from 10 to 20 mM, how-
ever, binding of zinc to plasma proteins lowers the free zinc
concentration to 0.5 to 1 mM.5 Zinc is present in the cytosol and
alpha granules of platelets at concentrations up to 60-fold
higher than in the plasma.3,5,6 Upon platelet activation, zinc
is released from platelets, contributing to a rise in the free zinc
concentrations of the plasma and in the microenvironment of a
growing thrombus.7,8
Endogenous zinc is also released or secreted from damaged
cells and can act as a paracrine agonist of zinc-dependent
signalling pathways in epithelial cells.9 Zinc has an acknowl-
edged role in haemostasis. Low zinc diets are associated with
platelet-related bleeding disorders in humans and rodents.10,11
Rats with acute and long term zinc deficiency have impaired
platelet aggregation responses to ADP and thrombin,11,12 and rats
fed with a high zinc diet show increased platelet responsiveness
to collagen, ADP, thrombin and adrenaline.13 Additionally, zinc-
deficient cancer patients exhibit cutaneous bleeding and platelet
dysfunction that is reversed by zinc supplementation.14
Zinc has previously been shown to be a platelet agonist, with
sub-millimolar concentrations of zinc being able to induce
aggregation. Low concentrations of zinc potentiate ADP-induced
platelet aggregation in an integrin aIIbb3 dependent manner.
15,16
However, the mechanism by which zinc causes platelet aggrega-
tion and its relative contribution to pathophysiological thrombus
formation remains unstudied.
Here we confirm that zinc is a platelet agonist at millimolar
concentrations, and is able to potentiate platelet activation at
low micromolar concentrations. Furthermore, we investigated the
mechanism of zinc-induced platelet activation using millimolar
zinc. Zinc gains access to the platelet cytosol and induces
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aggregation in a manner that is dependent on secondary
activators, intracellular calcium release and tyrosine phosphor-
ylation. The pattern of phosphorylated proteins is suggestive of
a novel signalling pathway.
Our data are consistent with a role for zinc in platelet activa-
tion during haemostasis and pathogenic thrombus formation.
Results
Zinc is a platelet agonist
Previous studies have shown that 0.5 mM ZnCl2 induces aggre-
gation in both platelet rich plasma (PRP) and washed platelets,
and that increasing the concentration further results in a reduced
response.15,16 We confirmed this observation with the use of
ZnSO4 (Fig. 1). Complete aggregation of washed platelets was
induced by 300 mM of ZnSO4 (Fig. 1A and B). Aggregation was
biphasic, indicating a reliance on secondary signalling. In agree-
ment with previous reports, increasing zinc above 1 mM led to a
reduced response. Of the other exogenously added cations tested
(NiSO4, LiSO4, CuSO4, CoSO4, MgSO4, MnCl2), only CuSO4 induced
a partial response (Fig. 1B).
Zinc-induced platelet aggregation involves secondary
mediators of platelet activation
In order to assess the influence of secondary signalling on zinc-
induced aggregation, platelets were pre-treated with antagonists
of secondary signalling pathways before being challenged with
diﬀerent concentrations of ZnSO4.
Pre-treatment with the aIIbb3 antagonist, GR144053 (2 mM)
abolished platelet aggregation in response to 1 mM ZnSO4
(Fig. 2A). Thus, zinc-induced activation results in aIIbb3-dependent
aggregation and is not dependent on cation-induced agglutina-
tion. Pre-treatment for 15 min with aspirin (1 mM), NF449
(P2X1 antagonist, 100 mM), 2-MeSAMP (P2Y12 antagonist, 100 mM)
or PGE1 (PG receptor antagonist, 2 mM) reduced zinc-induced
aggregation (Fig. 2A). This indicates roles for secondary activation
pathways (thromboxane A2 and purinergic signalling) in zinc-
induced aggregation, in addition to a role for cAMP in zinc-
mediated signalling.
The profile of aggregation traces following aspirin, MeSAMP
or NF449 treatment is suggestive of partial aggregation without
secondary activation (not shown). DM-BAPTA-AM pre-treatment
(10 mM) inhibited zinc-induced aggregation (Fig. 2A). This is
consistent with a requirement for intracellular signalling which
may include exogenous cation entry into the platelet cytosol or
cation release from intracellular stores. Pre-treatment with the
PKC antagonist GF109203X fully inhibited zinc-induced aggre-
gation (Fig. 2A), indicating that zinc-dependent signalling path-
ways converge on PKC. We further investigated the influence of
zinc on platelet activation with the membrane permeable zinc
chelator, TPEN. TPEN pre-treatment inhibited zinc-induced aggre-
gation to a similar degree to that caused by PGE1, indicating that
intracellular zinc is necessary for zinc-induced aggregation. The
concentration of TPEN used here (50 mM) was eﬀective when
platelets were activated with 1 mM ZnSO4, indicating that the
inhibitory eﬀect of TPEN was intracellular, and not caused by
chelation of extracellular zinc ions prior to platelet activation.
To further investigate the involvement of secondary signal-
ling, platelets were pre-treated for 15 min with a combination of
aspirin (1 mM), NF449 (100 mM) and MeSAMP (100 mM) before
being challenged with increasing concentrations of CRP-XL,
thrombin or ZnSO4. Whilst thrombin-induced aggregation was
abolished (Fig. 2B and E), CRP-XL (Fig. 2C and F) and zinc-
induced aggregation (Fig. 2D and G) were only partially inhibited.
Thus, zinc-induced activation relies on secondary platelet signal-
ling for a full aggregation response.
Zinc potentiates platelet reactivity to CRP-XL, thrombin and
adrenaline
The data described in Fig. 1 and 2 suggest that zinc-induced
platelet aggregation requires secondary agonists that are likely
to be released in a PKC-dependent manner. However, the con-
centrations of zinc used here (0.1 to 1 mM) are higher than
the local concentrations reported to occur during thrombus
formation.7 Therefore, we investigated the potential of sub-
activatory, pathophysiologically relevant zinc levels to potentiate
platelet activation to diﬀerent agonists. Sub-activatory concentrations
Fig. 1 Zinc, but not other cations, induces platelet aggregation. The eﬀect of
exogenous zinc on platelet activation was investigated using light transmission
aggregometry. (A) Representative experiment showing platelet responses
to diﬀering concentrations of ZnSO4. At intermediate concentrations,
ZnSO4 induced a biphasic aggregation response, suggestive of secondary
signalling-mediated activation. High concentrations of ZnSO4 (3 mM)
resulted in a reduced response. Similar aggregation traces were observed
using ZnCl2 (not shown). (B) Quantitation of aggregation traces indicates
that maximal aggregation was induced by 0.3 mM to 1 mM ZnSO4 (J).
CuSO4 induced partial aggregation at 1 mM (&). Other cations (NiSO4 n,
LiSO4}, CoSO4 , MgSO4 , MnCl2m) did not induce platelet aggregation.
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of 10 mM and 30 mM ZnSO4 were used as these are only an order
of magnitude greater than previously reported plasma free
zinc levels.5
Platelets potentiated with 30 mM ZnSO4 showed an increased
response to low concentrations of all agonists tested (Fig. 3).
Pre-treatment with 30 mM ZnSO4 followed by challenge with
0.01 mg mL1 CRP-XL resulted in 48.1  10.6% aggregation,
whereas non-potentiated platelets resulted in 10.1  5.0%
aggregation (Fig. 3A and D). Similarly, 0.03 U mL1 of thrombin
failed to induce aggregation whilst potentiation with zinc restored
aggregation to 60.6  16.2% (Fig. 3B and E). Treatment of control
platelets with adrenaline resulted in full aggregation following a
lag period. Preincubation with zinc shortened this lag period at all
adrenaline concentrations tested (Fig. 3C and F). For example,
1 mM adrenaline induced aggregation after a lag period of
586.6  35.4 s. ZnSO4 potentiation reduced this time to
333.3  29.1 s. Pre-treatment with 10 mM ZnSO4 did not
potentiate platelet activation to CRP-XL (not shown).
Zinc induces tyrosine phosphorylation of platelet proteins
Tyrosine phosphorylation is a platelet activatory signalling event
strongly induced by collagen and CRP-XL,17–19 and to a lesser
extent induced by other platelet agonists. To provide further
insight into the mechanisms responsible for zinc-induced aggre-
gation, the extent of tyrosine phosphorylation in the platelet
suspensions following treatment with zinc was examined.
Exogenous zinc (1 mM) induced tyrosine phosphorylation in
a time-dependent manner (Fig. 4A). Increased phosphorylation
of highmolecular weight proteins was visible after 30 s. Thrombin
(0.1 U mL1) induced few tyrosine phosphorylation events, as
previously reported20 (Fig. 4B). Interestingly, ZnSO4 treatment
(0.1 mM) induced a pattern of tyrosine phosphorylation which
differed from that observed in response to CRP-XL or thrombin.
High MW proteins phosphorylated by ZnSO4 treatment were
absent following CRP-XL treatment, whilst a low MW protein
(consistent in size with the FcgR19) was phosphorylated by
Fig. 2 Addition of exogenous ZnSO4 to platelets pre-treated with specific antagonists reveals a role for secondary signalling in zinc-induced
aggregation. (A) Platelets were treated with inhibitors before being challenged with 1 mM ZnSO4. Untreated platelets (J) or platelets pre-treated with a
combination of inhibitors (1 mM aspirin, 100 mMMeSAMP and 100 mMNF449,K) were challenged with diﬀerent concentrations of thrombin (B), CRP-XL (C),
or ZnSO4 (D). Representative aggregation traces following activation with 0.1 U mL
1 thrombin (E), 1 mg mL1 CRP-XL (F), 1 mM ZnSO4 (G).
Metallomics Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
8 
A
ug
us
t 2
01
5.
 D
ow
nl
oa
de
d 
on
 0
4/
11
/2
01
5 
17
:1
8:
49
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Metallomics This journal is©The Royal Society of Chemistry 2015
CRP-XL but not ZnSO4. Additionally, pre-treatment of platelets
with 50 mM TPEN resulted in increased tyrosine phosphorylation
of a high molecular weight protein (approximately 95 kDa). TPEN
reduced phosphorylation of platelet proteins following stimula-
tion with 0.1 mM ZnSO4 and 0.1 U mL
1 thrombin, but had little
effect on phosphorylation initiated by 1 mg mL1 CRP-XL.
Zinc-induced aggregation is independent of GpVI-mediated
activation, but upregulates GpVI activity
The mechanism by which zinc causes platelet aggregation is
unclear. As PKC and Ca2+ signalling are downstream of GpVI
engagement, we examined the involvement of GpVI in zinc-
induced activation. Pre-treatment of platelet suspensions with
the GpVI-blocking antibody, 1C3, resulted in a reduced response to
CRP-XL, whilst zinc-induced aggregation was unaﬀected (Fig. 5A).
1C3 reduced aggregation induced by 0.1 mg mL1 CRP-XL to
9.5 5.6%whilst 300 mMZnSO4 treatment resulted in 104.7 8.0%
aggregation (Fig. 5A and B). Thus, GpVI-functionality is not a
prerequisite for zinc-induced aggregation.
The influence of zinc on platelet adhesive receptor activity
was further investigated by examining receptor-specific platelet
adhesion using collagen-mimetic peptides. GR144053-treated
platelet suspensions treated with 100 mM ZnSO4 displayed a
significant increase in binding activity to GpVI-binding peptides
(CRP, III-1 and III-30), whilst binding to a2b1-binding peptides
(GFOGER, GLOGEN and II-28) was not aﬀected (Fig. 5C). For
adhesion to GpVI-adhesive peptides, A405 values were 0.8  0.1
and 1.4  0.2 for untreated and 100 mM zinc treated platelets
respectively on CRP, and 0.5  0.1 and 1.0  0.2 on III-30. On
GFOGER, absorbance values were 1.1  0.3 and 1.2  0.4 respec-
tively. These data indicate a selective role for zinc in increasing the
aﬃnity of GpVI for its cognate ligand.
Exogenous zinc gains access to the platelet cytosol
Zinc-induced platelet activation may occur as a result of zinc
entry into the platelet cytosol. To investigate this possibility
we loaded platelets with the zinc-sensitive indicator Fluozin-3
and assessed changes of fluorescence in response to exogenously
applied ZnSO4. Using fluorometry, concentration dependent
increases of fluorescence were observed following stimula-
tion of platelet suspensions by extracellular zinc (Fig. 6A). To
further assess the localisation of Fluozin-3 fluorescence con-
focal microscopy was employed. Fluozin-3-loaded platelets were
adhered to collagen-coated coverslips and changes of intra-
cellular fluorescence were imaged in response to exogenous
zinc. Treatment with 10 mM ZnSO4 following platelet adhe-
sion resulted in observable increases of intracellular fluores-
cence over time (Fig. 6B). This is consistent with increases in
Fig. 3 Sub-activatory concentrations of ZnSO4 potentiate platelet activation by other agonists. Platelet suspensions were pre-treated for 15 min with
sub-activatory concentrations (30 mM) of ZnSO4 before being challenged with diﬀerent concentrations of agonist. Representative aggregation traces
following CRP-XL- (A), thrombin- (B) or adrenaline- (C) stimulation of 30 mM ZnSO4 pre-treated platelets. Maximal aggregation was calculated for
CRP-XL- and thrombin-induced activation (D and E), and time to 50% aggregation was calculated for adrenaline-induced activation (F). J Untreated
platelets andK 30 mM ZnSO4 treated platelets.
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cytosolic zinc, demonstrating that exogenous zinc gains access
to the platelet cytosol.
TPEN inhibits platelet activation induced by multiple agonists
To investigate the role of zinc in intracellular signalling processes,
we examined aggregation of TPEN-treated platelets. Platelet aggre-
gation induced by CRP-XL, U46619 or ZnSO4 was fully abrogated
in TPEN-treated platelets, whilst aggregation induced by thrombin
or A23187 was inhibited at low agonist concentrations (Fig. 7A–E).
We used a whole-blood perfusion system with collagen
or collagen-mimetic peptides as substrates to examine
receptor-specific platelet adhesion and activation under physio-
logically relevant flow conditions (Fig. 7F–I).21
Surface coverage was relatively unaﬀected by TPEN treatment,
with an increase only being seen on a VWF-III/CRP surface (from
22.7  3.8% to 45.3  10.8%, Fig. 7G).
The end-point parameter ZV50 reports platelet–platelet inter-
actions, quantifying platelet activation under flow conditions
(Fig. 7H).21,22 On CRP/GFOGER, 50 mM TPEN reduced ZV50
from 3.6  0.3 mm to 1.2  0.2 mm, whilst on CRP/GFOGER/
VWF-III, ZV50 was reduced from 3.2 0.3 mm to 1.4 0.2 mm. On
VWF-III/CRP, ZV50 was reduced from 3.5 1.3 mm to 1.3 0.1 mm.
TPEN treatment did not affect ZV50 on any other surfaces. We used
‘‘platelet mobility’’ (PM) as a real time parameter to quantify the
effect of TPEN on stable platelet adhesion.22 On all surfaces tested,
PM was unaffected by TPEN treatment (Fig. 7I). Thus, TPEN
reduces platelet thrombus formation, without affecting the
ability of platelets to achieve stable adhesion.
Fig. 4 Zinc induces tyrosine phosphorylation of platelet proteins. (A) Platelet
suspensions were incubated with 1 mM ZnSO4 for increasing time periods.
Tyrosine phosphorylation of platelet proteins could be observed 30 s after
incubation. Platelet suspensions were activated for 15 min with 0.1 mg mL1
CRP-XL, 0.1 U mL1 thrombin or 0.1 mM ZnSO4 with stirring (B). Substantially
more tyrosine phosphorylation events were observed following GpVI-
dependent activation with CRP-XL than were observed following thrombin
activation. ZnSO4 also induced tyrosine phosphorylation of platelet proteins,
although the pattern was diﬀerent to that seen with CRP-XL. No phosphoryla-
tion of FcgRwas observed following ZnSO4 treatment. TPEN treatment (50 mM)
resulted in increased phosphorylation of a highmolecular weight protein. TPEN
inhibited ZnSO4- but not CRP-XL-induced phosphorylation.
Fig. 5 Zinc-induced platelet activation is independent of GpVI activity, but
upregulates GpVI-dependent platelet adhesion. Platelet suspensions were
treatedwith the GpVI blocking antibody, 1C3 for 5min before being challenged
with 0.3 mM ZnSO4 (A and B). Antibody treatment inhibited aggregation to
CRP-XL but not ZnSO4, indicating that GpVI activity is not required for zinc-
induced aggregation. (C) GR144053-treated platelet suspensions activated by
100 mM ZnSO4 displayed a significant increase in binding activity to GpVI-
adhesive peptides (CRP, III-1 and III-30), whilst binding to a2b1-adhesive
peptides (GFOGER, GLOGEN and II-28) was not aﬀected. & GR144053-
treated platelets, GR144053-treated platelets activated by 100 mM ZnSO4-
and’ GR144053-treated platelets pre-treated with 2 mM EDTA.
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Conclusions
The role of zinc in platelet activation and pathophysiological
thrombus formation has received little attention, despite having
been shown to be an important and physiologically relevant
cofactor in haemostasis.5,10,11,13,15,16 Zinc as a signalling factor
has been overlooked in favour of Ca2+, which is considered the
more important cation for platelet function owing to its higher
concentration and more readily observable fluctuations during
platelet activation.23 Whilst the work presented here does not
challenge this view, it should be noted that commonly used Ca2+
chelating agents and fluorophores have higher aﬃnities for zinc (for
example, the Kds of BAPTA for calcium and zinc are 160 nM and
0.5 nM respectively, whilst Fura-2 has Kds of 145 nM and 3 nM). Use
of such reagents may have resulted in an underestimation of the
role and significance of zinc in platelet activation.
Here we show that exogenous zinc gains access to the
platelet cytosol and is able to activate platelets. Chelation of
intracellular zinc results in a reduction of platelet aggregation,
tyrosine phosphorylation and thrombus formation under flow
conditions. These data support a transmembrane signalling
role for zinc in platelet activation.
We confirm previous observations that zinc is a potent
platelet agonist at millimolar concentrations, and can potentiate
platelet aggregation by other agonists at lower concentrations.
Free zinc is present in blood at a concentration of 0.5–1 mM
rising to 6–10 mM in the close proximity of platelet membranes.5
However, zinc is released from activated platelets and damaged
cells6–9 so is likely to be concentrated at sites of vascular injury.
It is not unreasonable to suggest that higher local concentra-
tions of zinc may be achieved in a growing thrombus, indicat-
ing that the potentiating effect observed here and by others2,15
may be pathophysiologically relevant.
Fig. 6 Exogenous zinc gains access to the platelet cytosol. (A) Fluorometric
imaging of Fluozin-3-stained platelet suspensions following addition of
increasing concentrations of ZnSO4. (B) Collagen-adhered Fluozin-3-
loaded platelets were perfused with 10 mM ZnSO4 and imaged by confocal
microscopy. This representative time-lapse image sequence shows increases
in cytosolic zinc approximately 20 s after onset of perfusion.
Fig. 7 TPEN inhibits platelet activation. Platelets were pre-treated with 50 mM TPEN (K) or vehicle (J) before being challenged with diﬀerent
concentrations of platelet agonists during aggregometry. (A) CRP-XL, (B) thrombin, (C) ZnCl2, (D) U46619, (E) A23187. In all cases a reduction in
aggregation as a result of TPEN treatment was observed. Platelets in whole blood were treated with 50 mM TPEN before being perfused across fibrillar
collagen, or combinations of collagen mimetic peptide as described in the text. (F) Representative images of platelet thrombi formed following pre-
treatment with vehicle (left panel) or 50 mM TPEN (right panel). Quantitative assessment of images of thrombi forming on thrombogenic surfaces under
flow conditions. (G) Thrombus or platelet surface coverage, (H) ZV50 and (I) plateau, derived from platelet mobility (PM, see Methods).
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Additionally, under conditions of extensive platelet activa-
tion, zinc concentrations may reach levels that could activate
platelets directly, contributing to thrombus formation.
In our experiments, we have used concentrations of zinc up
to and including millimolar levels. Whilst unlikely to represent
the physiological situation, these levels have allowed us to
probe the mechanisms by which platelets respond to zinc. This
strategy has been employed by others in the investigation of
platelet signalling pathways with diﬀerent agonists. For example,
the physiological concentration of collagen experienced by plate-
lets during vascular injury is not known, but high concentrations
of CRP-XL have been used to investigate GpVI function.19,24,25 To
address the pathophysiological significance of zinc, we also used
lower concentrations of zinc to investigate potentiation of plate-
let activation. Zinc-induced platelet aggregation is sensitive to
inhibition of aIIbb3, demonstrating an activatory eﬀect, rather
than non-specific cation-induced agglutination. We provide
evidence that zinc is not an extracellular stimulus, but gains
access to the platelet cytosol to activate platelets. Zinc entry into
platelets was observed with confocal microscopy and fluoro-
metry using Fluozin-3 stained platelets. Other cations that have
previously been shown to activate integrins (such as Mn2+)26
had no eﬀect on platelet aggregation.
The eﬀect of intracellular chelating agents, BAPTA-AM and
TPEN, is consistent with an intracellular eﬀect of zinc, either by
directly accessing the cytosol or by activating intracellular
signalling processes. Furthermore, complete blockade of zinc-
induced aggregation following inhibition of PKC indicates that
intracellular biological processes are required for zinc-induced
aggregation. These data all provide strong evidence for an active,
dynamic transmembrane signalling role for zinc in platelet
activation.
The mechanism by which zinc gains access to the platelet
cytosol is not known. Zinc, and other divalent cation channels
and transporters are present in the platelet proteome, but have
yet to be investigated in the context of zinc induced activation.
Assessment of the roles of specific channels or transporters in
zinc entry must await future studies utilising specific blocking
agents. Identification of such blocking reagents would assist in
the evaluation of the physiological relevance of zinc in platelet
behaviour. It is important to note that our experiments have
been carefully designed to preclude contributions by exogenous
Ca2+ (i.e. nominally Ca2+-free salines). Whilst these conditions
are somewhat removed from the physiological situation, we
observe normal platelet aggregation responses to the major
agonists CRP-XL, thrombin and U46619 (Fig. 2 and 7). However,
we cannot exclude the possibility that zinc-induced aggregation
coincides with the release of intracellular Ca2+ and activation of
store operated Ca2+ entry. Extracellular Ca2+ has previously been
shown to be required for platelet responses to phorbol-myristate
acetate (PMA) in zinc deficient rats.27 It is intriguing to postulate
that zinc and calcium may have a synergistic relationship. This
remains an important area of study and will be the focus of
future research.
Zinc-induced activation resulted in tyrosine phosphorylation
of platelet proteins, granule release and secondary activation
leading to aIIbb3 activation, whilst zinc chelation inhibited
phosphorylation and aggregation in response to multiple agonists.
This indicates a correlation between zinc-induced phosphorylation
and aggregation.
Similarities were observed between GpVI- and zinc-induced
platelet activation. Both involve substantial protein tyrosine
phosphorylation, and both are less dependent on secondary
signalling than thrombin-induced aggregation. However, the
pattern of protein phosphorylation induced by the two agonists is
suﬃciently diﬀerent to suggest an alternative mechanism. The
absence of clear FcgR phosphorylation following zinc treatment
suggests that zinc acts downstream of GpVI dimerization and Src-
dependent FcgR phosphorylation. However, this is not consistent
with the observation that zinc causes upregulation of GpVI-
dependent platelet adhesion. The nature of the increased adhe-
sive response of GpVI is not known, but may involve promotion
of receptor dimerization.25 This may be regulated by increases in
cytosolic zinc concentrations or by a direct extracellular eﬀect on
GpVI. Our results are suggestive of an inside-out and outside-in
scheme of GpVI regulation that is reminiscent of integrin beha-
viour in platelets and other cells. This is a novel and interesting
possibility that warrants further research.
Involvement of PKC in zinc-induced aggregation is inferred
from inhibition of aggregation by PKC inhibitors. Whether an
increase in cytosolic calcium is required for zinc-induced activa-
tion is not known and would be diﬃcult to assess empirically
due to the higher aﬃnity for zinc over calcium of conventional
calcium indicators and chelators. However, zinc has also been
shown to aﬀect PKC activity in platelets and lymphocytes, by
increasing association with the cell membrane.28 Additionally,
the biphasic aggregometry response to zinc indicates a role for
granule release in full activation, further implicating PKC in
zinc-induced aggregation.29 This is further supported by the
observation that combined inhibition of P2Y12, P2X1 and
thromboxane signalling results in partial aggregation following
zinc treatment (an inhibition-resistant activation profile) demon-
strating elements of an activatory response that are independent
of granule release. Again, this resembles GpVI-rather than
thrombin-induced aggregation and may reflect partial increase
of aIIbb3 activity in the absence of secondary signalling.
The phosphorylation of high molecular weight proteins
indicates that kinase or phosphatase activity is aﬀected by
exogenous zinc. The pattern of phosphorylation diﬀered from
that of GpVI- and protease activated receptor (PAR) dependent
phosphorylation, suggesting the involvement of diﬀerent
kinases and substrates. Interestingly, chelation of intracellular
zinc with TPEN resulted in the phosphorylation of a 95 kDa
protein, indicating the activity of kinases or phosphatases that
are sensitive to intracellular zinc levels. TPEN treatment inhibited
zinc- and PAR-dependent protein tyrosine phosphorylation but
had little eﬀect on GpVI-mediated phosphorylation. This may
indicate conservation of PAR and zinc-dependent signalling
mechanisms.
Zinc is released from platelets and is likely to aﬀect platelets
within a growing thrombus.7 However, the extent of the influence
of zinc on pathophysiological thrombus formation is not known.
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Here, we demonstrate that chelation of intracellular zinc inhibits
thrombus formation under physiologically relevant flow conditions.
This work does not directly investigate signalling, but high-
lights a role for zinc in platelet activation. Given the number
and variety of zinc-binding proteins in the platelet cytosol, an
eﬀect on activation is not surprising.
Potentiation of platelet aggregation with sub-activatory levels
of zinc may provide evidence for a physiological role of zinc in
platelet activation. Potentiation increased the eﬃcacy of low
concentrations of platelet agonists that act via GpVI and PARs.
Interestingly, potentiation of adrenaline-induced activation led
to a reduction in the time taken to achieve aggregation, but not
in the final extent of aggregation. We propose that zinc released
from activated platelets or damaged cells will potentiate the
activation of other platelets in a growing thrombus. This hypo-
thesis will be testable following the identification of specific
antagonists that block zinc entry into platelets.
In conclusion, our data confirm previous observations of a
role for zinc as a platelet agonist. We provide data demonstrat-
ing a potentiating role for sub-activatory levels of zinc during
platelet activation by other agonists. Zinc enters the platelet
cytosol and regulates protein phosphorylation-dependent platelet
signalling events, leading to granule release and full PKC-mediated
aIIbb3-dependent aggregation. Although similarities exist between
zinc-activation and GpVI or PAR-mediated activation, suﬃcient
diﬀerences remain to suggest a novel mechanism. Furthermore,
chelation of platelet zinc inhibits platelet activation and tyrosine
phosphorylation, indicating a role for intracellular zinc in platelet
function. Whilst this work does not address the physiological
relevance of zinc in thrombus formation, we speculate that zinc
is acting as a transmembrane signalling ion.
Experimental
Ethical approval
Whole blood was obtained from healthy volunteers, free from
medication for two weeks, after consent in accordance with the
Declaration of Helsinki and our Institutional guidelines, as
approved by the local ethics committee.
Materials
NF449 (4,40,400,40 0 0-[carbonyl bis(imino-5,1,3-benzenetriyl-bis-
(carbonylimino))]tetrakis-1,3-benzenedisulfonic acid, octasodium
salt), 2-MeSAMP (methylthioadenosine 50-monophosphate triethyl-
ammonium salt hydrate) and GF109203X (2-[1-(3-dimethyl-
aminopropyl)indol-3-yl]-3-(indol-3-yl) maleimide) were from
Tocris, UK. Fluozin-3-AM was from Invitrogen, UK. GR144053
(4-[4-[4-(aminoiminomethyl)phenyl]-1-piperazinyl]-1-piperidine-
acetic acid trihydrochloride hydrate) was from Novabiochem,
UK. PPACK (Phe-Pro-Arg-chloromethylketone) was fromCambridge
Bioscience, UK. Bovine tendon collagen I fibres were the gift of
Ethicon Corp (New Jersey, USA). The anti-GpVI ScFv 1C3 has
previously been described.30 TPEN (N,N,N0,N0-tetrakis(2-pyridyl-
methyl) ethylenediamine), aspirin, prostaglandin E1 (PGE1),
DiOC6 (3,30-dihexyloxacarbocyanine iodide), DM-BAPTA-AM
(dimethyl-1,2-bis(o-aminophenoxy)ethane-N,N,N0,N0-tetraacetic acid)
and other chemicals were from Sigma-Aldrich, UK. Cross-linked
CRP (CRP-XL) was prepared as previously described.17 Collagen-
mimetic peptides were prepared as previously described.21,31–33
Peptides used in these experiments included:
CRP: GCO(GPO)10GCOG-amide (where O indicates hydroxyproline);
GFOGER: GPC(GPP)5GFOGER(GPP)5GPC-amide
VWF-III: GPC(GPP)5GPRGQOGVMGFO(GPP)5GPC-amide
GLOGEN: GPC(GPP)5GLOGEN(GPP)5GPC-amide;
GPP10: GPC(GPP)10GPC-amide;
III-1: GPC(GPP)5GLAGYOGPAGPOGPOGPOGTSGHOGSO(GPP)5GPC-amide
III-12: GPC(GPP)5GQRGEOGPQGHAGAQGPOGPOGINGSO(GPP)5GPC-amide;
III-30: GPC(GPP)5GAOGLRGGAGPOGPEGGKGAAGPOGPO(GPP)5GPC-amide;
III-33: GPC(GPP)5GEOGGOGADGVOGKDGPRGPTGPIGPO(GPP)5GPC-amide.
Platelet preparation
Whole blood was collected into 11 mM sodium citrate and
centrifuged to obtain PRP (240 g, 15 min). 2 mM prostaglandin
E1 (PGE1, Sigma-Aldrich) was added and the PRP centrifuged
(640 g, 15min). The pellet was resuspended to 2 108 platelets per
mL in calcium-free Tyrodes buﬀer (CFT, 10 mM N-2-hydroxy-
ethylpiperazine-N0-2-ethanesulfonic acid (HEPES), 140 mM NaCl,
5 mM KCl, 1 mM MgCl2, 5 mM glucose, 0.42 mM NaH2PO4,
12 mM NaHCO3, pH 7.4). Platelet suspensions were rested for
30 min at 37 1C before use.
Aggregometry
Aggregation experiments were performed at 37 1C in an AggRam
aggregometer (Helena Biosciences, UK). Briefly, 250 mL of platelet
suspension was aliquotted into a cuvette along with a magnetic
stir bar. 100% aggregation was calibrated using CFT. Agonists or
antagonists were added (1% v/v) and aggregation was recorded
with stirring (1000 rpm) for 15 min. Maximal aggregation and the
time to 50% aggregation were calculated. Platelet suspensions
were treated with inhibitors, potentiating concentrations of ZnSO4
(indicated in the text) or vehicle control for 15 min prior to each
experiment.
Western blotting
Western blotting was performed as described previously.34 Briefly,
washed platelet suspensions (2  109 mL1) were stimulated
under stirring conditions in the presence of reagents stated
in the text. At given time points, platelets were lysed and boiled
for 5 minutes. Samples were resolved by 10% SDS-PAGE and
transferred onto a nitrocellulose membrane. Membranes were
probed with an anti-phosphotyrosine primary antibody (4G10;
Fisher, UK) and anti-mouse HRP-conjugated secondary anti-
bodies. Equal amounts of proteins were loaded onto each lane,
and was assessed by coomassie blue staining of the nitrocellulose
membrane. Data are representative of a minimum of three
independent experiments using platelets from diﬀerent donors;
representative blots are shown.
Intracellular zinc measurements of Fluozin-3-stained platelets
For fluorometry, PRP was incubated with 2 mM Fluozin-3-AM
(Invitrogen) for 45 min at 37 1C. Platelets were collected by
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centrifugation (350 g, 20 min) and resuspended in CFT to 8 
108 mL1. Fluorescence was recorded from 1.5 mL stirred
aliquots of platelet suspension at 37 1C using a Cairn Research
Spectrophotometer (Cairn Research, UK) with excitation at 488 nm
and emission at 516 nm. For confocal microscopy, Fluozin-3-
stained platelets were adhered to type I collagen fibres on a
coverslip for 15 min. Following washing, adhered platelets were
perfused with 10 mM ZnSO4, during which images were acquired
using FV300 laser-scanning confocal microscope (Olympus, UK)
with excitation at 488 nm and emission at 510–530 nm.
Static adhesion assay
The adhesion of platelets to collagen or collagenmimetic peptides
adsorbed to microtitre plates under static conditions at 21 1C after
60 min was measured using a colorimetric assay as previously
described.35,36 The peptides used included ligands for GpVI (CRP,
III-1, III-30, type I collagen),36 integrin a2b1 (II-28, GLOGEN, type I
collagen),35 and inert peptides (GPP10, III-12 and III-33).
36
Confocal microscopy
For perfusion studies, whole blood was taken into 40 mM PPACK,
supplemented with 10 mM PPACK hourly. Platelets in whole blood
were stained with 5 mM DIOC6 for 15 min before use. Perfusion
studies were performed as described21,22 with some modification.
Briefly, glass coverslips were coated with collagen fibres or combi-
nations of collagen-mimetic peptides. Each peptide, dissolved in
0.01 M acetic acid, was coated at 0.1 mg mL1 in a mixture
containing a total of 0.3 mg mL1 of peptide. For surfaces where
only 1 or 2 active peptides were applied, the total peptide concen-
tration was made up to 0.3 mg mL1 with the inert homolog
GPP10. Collagen was coated at 0.1 mg mL
1. Coverslips were
covered with peptide solution and held in a humid chamber
overnight at 4 1C. After removal of excess fluid, they were blocked
with 1% bovine serum albumin in HEPES buﬀer (36 mM NaCl,
2.7 mM KCl, 5 mM HEPES, 10 mM glucose, 2 mM MgCl2, 2 mM
CaCl2). The coverslip, in a 125 mm deep flow chamber, was
mounted on an FV300 laser-scanning confocal microscope
(Olympus, UK) and washed for 1 min with HEPES buﬀer. Blood
was drawn through the chamber for 5 min using a syringe pump
at a calculated wall shear rate of 1000 s1 after which residual
blood was flushed using HEPES buﬀer before image acquisition.
Where stated, whole blood was pre-incubated with TPEN for 15min
at 37 1C. Images were acquired at 0.2 Hz (for morphology experi-
ments) and subjected to image analysis to generate parameters of
thrombus formation including surface coverage and ZV50. ZV50
quantifies the height of a field of thrombi at which the thrombus
volume is half maximal. This value correlates with platelet activa-
tion.21 Additional dynamic parameters of platelet mobility were
calculated as previously described.22 The parameter reported here
(plateau) reports the relationship between the extent of stable
adhesion achieved by a platelet population and perfusion time.
Data analysis
Values are expressed as the mean standard error of the mean.
Experiments were repeated on at least four occasions using
blood from diﬀerent donors. Diﬀerences among mean values
were identified using analysis of variance, and post hoc com-
parisons used Student–Newman–Keuls or Student t tests with
residual degrees of freedom and residual mean square to calculate
pooled SD.
Abbreviations
PKC Protein kinase C
CRP-XL Cross linked collagen-related peptide
ADP Adenosine diphosphate
ATP Adenosine triphosphate
PRP Platelet rich plasma
PPACK Phe-Pro-Arg-chloromethylketone
PGE1 Prostaglandin E1
CFT Calcium free Tyrodes buﬀer
aIIbb3 Integrin aIIbb3.
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